MedCity News July 28, 2021
Frank Vinluan

The engineered viruses used to deliver gene therapies can spark complications and they can’t be re-dosed. Ring Therapeutics says viruses that evolved with humans can be better viral vectors and the startup has raised $117 million in new financing to continue its research.

Gene therapy reaches its cellular destination aboard an engineered virus, but the journey is not always problem free. Adeno-associated virus (AAV), the virus that is the backbone of many approved and experimental gene therapies, is foreign to the body and can therefore prompt dangerous immune responses. Even if those complications don’t develop, any antibodies the immune system produces against the viral vector means a patient can’t be given a second dose if needed because the antibodies will...

Today's Sponsors

Transcarent
SalesSparx
Canton & Company

Today's Sponsors

Oscar
Curation Health

Today's Sponsor

TripleTree

 
Topics: Biotechnology, Investments, Pharma / Biotech, Trends
Venture firms warn R&D funding for new drugs will 'drop off a cliff' if Dem bill approved
Contentious report suggests safety net hospitals leveraging discounts to pocket strong gains from cancer drugs
Adrian Cheng Moves Deeper Into Healthcare Industry With Artisan Merger Of Prenetics At $1.2 Bln Valuation
Complexities of COVID-19 manufacturing
340B hospitals mark up cancer drugs 3.8X for commercially insured patients, study finds